Noxopharm Ltd. · ASX:NOX
Noxopharm — Shareholder Meeting (November 2017)
35 slides from Noxopharm's shareholder meeting presentation, Nov 27, 2017
Slide 1: NOX AGM Corporate Presentation
Date: 27 November, 2017 Sydney, Australia For personal use only ASX Limited 20 Bridge Street NOX AGM CORPORATE PRESENTATION SYDNEY NSW 2000 ASX: NOX Sydney, 27th November 2017: Noxopharm Limited (ASX:NOX) is pleased to provide to the market and shareholders the Corporate Noxopharm Limited Presentati
Slide 2: CEO Review 2017 AGM
Noxopharm For personal use only 1 CEO REVIEW 2017 AGM 1
Slide 3: Our objectives
Noxopharm Our objectives For personal use only 2 For the doctor: 🔵 Drugs that boost the effectiveness of radiotherapy (and chemotherapy) ONCOLOGY …. with lower (better tolerated) treatment dosages For the patient: 🔵 Better survival outcomes without fewer side-effects For the investor: 🔵 A…
Slide 4: Radiotherapy: the best anti-cancer treatment we have
Radiotherapy … the best anti-cancer treatment we have Noxopharm For personal use only 3 DNA before and after radiation 3
Slide 5: Limitation of radiotherapy: dose-limiting toxicity
Limitation of radiotherapy Noxopharm 1. Dose-limiting toxicity For personal use only 4 4
Slide 6: Limitation of radiotherapy: metastatic cancer too extensive
Limitation of radiotherapy Noxopharm 2. Metastatic cancer too extensive for radiation For personal use only 5
Slide 7: DARRT: Direct and Abscopal Response to Radio-Therapy
Noxopharm For personal use only 6 DARRT Direct and Abscopal Response to Radio-Therapy 6
Slide 8: Direct sensitisation of radiotherapy
Noxopharm DIRECT Sensitisation of Radio-Therapy For personal use only 7 DNA damaged. Cell attempts to repair the damage. Extensive damage .. beyond repair……cell dies. Modest damage … repairable …. cell lives. Most dosages of radiotherapy not high enough to deliver extensive damage to all cancer cell
Slide 9: Direct response to radiotherapy
DIRECT Response to Radio-Therapy Noxopharm For personal use only 8 Radiotherapy applied to large Shrinkage of irradiated Direct radio-sensitising effect tumours tumours for pain relief 8
Slide 10: Direct response to radiotherapy with NOX66
DIRECT Response to Radio-Therapy Noxopharm For personal use only 9 NOX66 Radiotherapy applied to large Shrinkage of irradiated Complete remission of Direct radio-sensitising effect Direct radio-sensitising irradiated tumours effect tumours for pain relief tumours 9
Slide 11: Abscopal response to radiotherapy
ABSCOPAL Response to Radio-Therapy Noxopharm 10 For personal use only Exposed tumours respond Non-exposed tumours respond Low-dose radiotherapy Direct radio-sensitising Remission of irradiated effect tumours Abscopal response 10
Slide 12: Features of an abscopal response
Noxopharm Features of an abscopal response For personal use only 11 Rare – very rare phenomenon Complete – primary AND secondary tumours disappear Durable – potentially permanent Unrestricted – range of cancers reportedly involved Short treatment – single course of treatment (7-14 days) Low toxicity
Slide 13: How might an abscopal response work?
Noxopharm How might an abscopal response/bystander effect work? For personal use only 12 12
Slide 14: DARRT: external beam radiotherapy study design
DARRT Noxopharm For personal use only 13 Direct Effect Abscopal Effect Ø Patients with multiple (>3) tumours Ø Irradiate 1-2 tumours (5 days) External Beam RT Ø NOX66 14 days Ø Scan + 2 months and 4 months 13
Slide 15: DARRT: cancers targeted with external beam RT
DARRT Noxopharm For personal use only 14 Direct Effect Abscopal Effect Ø Prostate cancer (metastatic castrate-resistant) Ø Solid common cancers (eg. lung, breast, melanoma) External Beam RT Ø Rare cancers (eg. sarcomas) 14
Slide 16: DARRT: brachytherapy with LuPSMA
DARRT Noxopharm For personal use only 15 Direct Effect Abscopal Effect Ø 177 Lutetium-PSMA-617 Ø 4 x monthly intravenous injections of LuPSMA/10 Brachytherapy days NOX66 Ø Prostate cancer (metastatic castrate-resistant) Ø ? Kidney cancer 15
Slide 17: DARRT: NOX66-001 Phase 1b study with carboplatin
DARRT Noxopharm For personal use only 16 Where NOX66 + Radiotherapy needs a boost ……… NOX66-001 Phase 1b Study Georgia + Low-dose carboplatin (AUC4 – monthly) 400 mg NOX66 5 patients: 1 progressive; 4 non-progressive 800 mg NOX66 6 patients: 5 non-progressive; 1 partial response 16
Slide 18: Clinical pipeline
Noxopharm Clinical pipeline For personal use only 17 NOX66 + external beam radiotherapy + brachytherapy + chemotherapy (carboplatin) Idronoxil + intravenous dosage form + pessary dosage form 17
Slide 19: NOX66 Clinical Development Strategy
Noxopharm For personal use only 18 NOX66 Clinical Development Strategy Ian Minns Director, Clinical Development and Medical Affairs 18
Slide 20: NOX66 Clinical Development
Noxopharm For personal use only 19 NOX66 Clinical Development • Review of 2017 – Where are we now? • Looking forward to 2018 – Where are we heading? • Moving NOX66 towards first registration - Radiotherapy • Chemotherapy and other research with NOX66 • Sharing our progress • Communicating data in 20
Slide 21: Review of 2017: mid-year update
Noxopharm For personal use only 20 Review of 2017 – Where are we now? Mid-Year update Studies planned: 1. Chemotherapy (Carboplatin): Study Commenced (Georgia) 2. Radiotherapy: External Beam RT in prostate cancer (Australia) 3. Radiotherapy: Stereotactic RT in prostate cancer (Investigator) 4. Radio
Slide 22: Review of 2017: six months later
Noxopharm Review of 2017 – Where are we now? For personal use only 21 Mid Year update à 6 months later Studies planned: 1. Chemotherapy (Carboplatin): Study Commenced Recruitment completed, interim data presented 2. Radiotherapy: External Beam RT in prostate cancer Open for Recruitment 3. Radiothera
Slide 23: Review of 2017: moving to first registration
Noxopharm Review of 2017 – Where are we now? For personal use only 22 Mid Year update à 6 months later à Moving to first registration Studies planned: 1. Chemotherapy (Carboplatin): Study Commenced 2. Radiotherapy: External Beam RT in prostate cancer Open for Recruitment 3. Radiotherapy: Stereotacti
Slide 24: Moving towards first registration study
Noxopharm Moving towards first registration study For personal use only 23 Target Indication: NOX66 in combination with Radiotherapy for the Notes: treatment of patients with metastatic cancer • Different Global Regulators may modify indication for specific tumour types Studies: • Indication may als
Slide 25: Moving towards first registration
Noxopharm For personal use only 24 Moving towards first registration Notes: Target Indication: NOX66 in combination with Radiotherapy for the • Different Global Regulators treatment of patients with metastatic cancer may modify indication for specific tumour types Studies: • Indication may also list
Slide 26: Beyond the trials to reach registration
Noxopharm For personal use only 25 Beyond the trials to reach registration • Manufacturing and formulation: Optimise NOX66 formulation; GMP Manufacturing • Pre-clinical / non-clinical: in vitro and animal studies to meet regulatory and other requirements for registration and marketing • Medical Affa
Slide 27: Chemotherapy with NOX66
Noxopharm For personal use only 26 Chemotherapy with NOX66 - Which Combination(s)? - Which tumour type(s)? - When in disease pathway? - For how long? https://en.wikipedia.org/wiki/Chemotherapy_regimen 26
Slide 28: Chemotherapy with NOX66: plans
Noxopharm For personal use only 27 Chemotherapy with NOX66 • Radiotherapy prioritised for pathway to registration • Duration of therapy and of trials • Clarity of treatment (i.e. combination with RT) across all tumours • Chemotherapy remains important to development • NOX66-001 study to complete in
Slide 29: Communicating trials progress 2018
Noxopharm Communicating Trials Progress 2018 For personal use only 28 • Progress – based on Data Safety Monitoring Committee Review • Independent body – researchers and statisticians • Regular meetings during trials – expect ~6 across trials in 2018 • Review overall progress à decisions on continuat
Slide 30: What will 'good response' look like?
Noxopharm For personal use only 29 What will ‘good response’ look like ??? • Looking at a new breakthrough cancer treatment: • In Non-Small Cell Lung Cancer trial (582 patients evaluated) • Compared with a standard Chemotherapy • Median (50% of patients) overall Survival - 12.2 months compared with
Slide 31: NOX66 clinical studies in Asian-centric cancers
Noxopharm For personal use only 30 🔵 NOX66 clinical studies in Asian-centric cancers • Hepatocellular carcinoma (liver cancer) • Gastric carcinoma 🔵 Identify KOLs and form collaborations 🔵 Identify potential partners. 30
Slide 32: Non-oncology candidates
Noxopharm For personal use only 31 • Stroke • Concussion NYX-104 • Head trauma • Hearing loss • Peripheral • High neuropathy NYX-330 cholesterol NYX-205 • Ulcerative colitis • Sclerosing cholangitis 31
Slide 33: Key Messages
Noxopharm For personal use only 32 Key Messages WE EXPECT TO KNOW BY END OF 2017 OF THE SUCCESS OF OUR MISSION WE AIM TO BE IN A REGISTRATION STUDY BY END OF 2018 WE AIM TO HAVE MARKETING APPROVAL BY 2022 A SUCCESSFUL OUTCOME IS A MAJOR SHARE OF THE $100 BILLION ONCOLOGY DRUG MARKET REALISTIC POTENT
Slide 34: Disclaimer
For personal use only Disclaimer • This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or
Slide 35: Contact
For personal use only Contact 34